Objective. To develop response criteria for juvenile dermatomyositis (DM).
Methods. We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique.
Results. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute percent change in core set measures of minimal ( ‡30), moderate ( ‡45), and major ( ‡70) improvement. The same criteria were chosen for adult DM/ polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P 5 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P < 0.006).
Conclusion. The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.
Juvenile dermatomyositis (DM) is a systemic autoimmune disease characterized by chronic skeletal muscle inflammation and weakness. Core set measures to assess juvenile DM disease activity have been established and validated by the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology International Trials Organisation (PRINTO), with provisional endorsement by the American College of Rheumatology and the European League Against Rheumatism (1) (2) (3) (4) (5) (6) . Both core sets include physician and parent global activity, muscle strength, and physical function. IMACS also includes the most abnormal serum muscle enzyme value and extramuscular global activity, whereas PRINTO includes instead a health-related quality of life measure, the Child Health Questionnaire (7) and a global activity score, the Disease Activity Score (8) . IMACS measures muscle strength using manual muscle testing, and PRINTO measures muscle strength using the Childhood Myositis Assessment Scale (1, 2, 5) .
Combinations of these measures to determine clinical improvement were developed to enhance the sensitivity of responses and decrease the sample sizes needed, by using large prospective natural history data sets and expert clinician consensus as the gold standard. For both PRINTO and IMACS, at least 20% improvement in 3 of 6 core set measures with no more than 1 or 2 worsening (which cannot be muscle strength) had been established as preliminary response criteria, and additional combinations of improvement in the core set measures serve as secondary response criteria (9, 10) . PRINTO adapted its top criteria for minimal clinical improvement to moderate and major improvement by using cutoffs of 50% and 70%, similar to the improvement criteria for juvenile idiopathic arthritis (JIA) (11) (12) (13) .
Although the preliminary response criteria for juvenile DM advanced the assessment of patients and their responses to treatment, those criteria were limited by differences in the core set measures and final consensus response criteria between IMACS and PRINTO, a lack of randomized controlled trial data for full validation, and inadequate exploration of more sensitive approaches using hybrid or continuous methods (14) . The preliminary response criteria also considered each core set measure equally rather than differentially weighting them. However, most myositis experts agree that some core set measures are more important, such as physician global activity and muscle strength (3, 15) . For PRINTO studies, physician global evaluation of disease activity, muscle strength, and parent global evaluation of the child's overall well-being were weighted as the most important core set measures in a logistic regression analysis (3, 10 or major improvement. There is, therefore, a clear need to have standardized improvement criteria for all levels of improvement in future clinical trials, similar to the standardized criteria developed for rheumatoid arthritis (RA) and JIA.
For these reasons, IMACS and PRINTO engaged in a joint effort to develop fully validated response criteria for juvenile DM, including criteria for minimal, moderate, and major clinical response. This report focuses on the consensus conference in which the top candidate definitions of response leading to the final juvenile DM response criteria were considered.
Methods
In previous reports (16, 17) , we described the methodology used a) to create patient profiles using natural history data and obtain expert consensus on minimal, moderate, and major improvement (16) , b) to determine differential weights of the core set measures using conjoint analysis, and c) to draft 6 types of candidate definitions for response criteria using the myositis expert survey on thresholds of improvement and data-driven methods, such as logistic regression and conjoint analysis (Table 1) .
Conjoint analysis is a choice modeling or discrete choice experiment, which is a valid methodology for developing composite criteria and has been used recently in rheumatology (19) (20) (21) (22) . In the conjoint analysis surveys administered using 1000Minds online software (23) , experts were presented with pairs of hypothetical patient scenarios; each patient had different levels of improvement in the same 2 core set measures, assuming other core set measures remained the same. Experts rated which of the 2 scenarios had greater improvement. Based on the rater's response, the relative weights of core set measures and their levels of improvement were established and used to develop a scoring system by mathematical methods based on linear programming (24) such that when all 6 core set measures are considered together, the maximum score (total improvement score) possible for representing a patient's improvement is 100, and the minimum score is 0.
We then compared the performance characteristics of the drafted definitions in the patient profiles, using expert consensus ratings as a gold standard, and externally validated the candidate response criteria by applying them to clinical trial data. This process led to the development of traditional categorical as well as continuous candidate definitions for response criteria, with thresholds for minimal, moderate, and major improvement (18) . Continuous candidate definitions can also be considered hybrid definitions, because the same definition can be used either as a continuous outcome measure by using the total improvement score or as a categorical outcome measure by using the thresholds for minimal, moderate, and major improvement.
Candidate definitions were evaluated using consensus profile ratings as the gold standard, by assessing sensitivity, specificity, and area under the curve (AUC) to compare the performance of these candidate definitions. Those that performed well in the consensus profiles (sensitivity and specificity both $80%, AUC $0.9 for minimal, and AUC $0.8 for moderate and major improvement, using IMACS or PRINTO core set measures [1] ) were externally validated. The PRINTO trial randomized patients with new-onset juvenile DM to receive prednisone alone (n 5 47) or prednisone combined with methotrexate or cyclosporine (n 5 46 patients per treatment arm) (13) . Chi-square analysis was used to compare the percentages of patients meeting the candidate definitions for response at the primary end point (6 months) for the combined treatment arms versus the prednisone-alone (placebo) arm. Definitions with a significant difference (P , 0.05) between treatment arms for minimal improvement were further considered. Both PRINTO and IMACS core set measures were available in this trial.
A second trial validation data set included 48 juvenile DM patients enrolled in the Rituximab in Myositis (RIM) trial for treatment-refractory patients. It had a randomized placebophase design in which patients received either rituximab or placebo at weeks 0 and 1, and at weeks 8 and 9 their treatment assignment was reversed in a blinded manner (25) . We used the Mann-Whitney U test to determine whether each candidate definition could differentiate between the treating physician's rating of improvement (score range 1-7) at 6 months, a time point when most patients improved and that was also comparable to that in the PRINTO trial. For the RIM trial, only the IMACS core set measures were available.
We then selected the top candidate definitions, up to 4 top-performing definitions from each of the 6 different types of candidate definitions (Table 1) , for consideration at the final consensus conference as a manageable number of definitions to discuss.
Consensus conference. Nominal group technique was used at a consensus conference held in Paris, France on June 9-10, 2014, led by experienced moderators (LGR and NR, for the pediatric working group). The methodologies used to develop the new candidate response criteria and performance characteristics of each type of candidate definition were reviewed with the participants in a general session. The 12 pediatric working group participants first independently and then as a group reviewed the performance characteristics of the 14 top candidate definitions of response criteria for juvenile DM. Data for minimal, moderate, and major clinical response were presented for each definition, including a detailed spreadsheet that included the performance in the patient profiles using the IMACS and PRINTO core set measures, including sensitivity, specificity, AUC, as well as kappa values and odds ratios. AUC was defined as the average of the sensitivity and specificity values for all categorical candidate definitions, as well as for thresholds for minimal, moderate, and major improvement in continuous candidate definitions. In addition, for continuous definitions, an AUC for the total improvement score was determined from the receiver operating characteristic (ROC) curve as a plot of sensitivity versus (1 -specificity) for total improvement scores as well as for thresholds (26) (27) (28) . Results of the external validation for each candidate definition from the PRINTO and RIM clinical trial data sets were also presented.
Pediatric working group. After reviewing the performance of the 14 top performing candidate definitions, the 12 pediatric working group participants developed consensus response criteria for minimal, moderate, and major improvement in juvenile DM. The participants were informed of the secondary goal of reaching consensus on response criteria for both juvenile DM and adult DM/polymyositis (PM). Participants were first asked to rank their top 5 choices, considering the data presented, based on face validity, feasibility, and generalizability, and to determine which response criteria were most clinically meaningful. The voting process was conducted in a systematic manner with a predetermined format using nominal group technique (29, 30) facilitated by an internetbased system developed by staff at the PRINTO coordinating center (31, 32) . Voting was done anonymously and independently using the online voting software. After the initial round of voting, the results were shared with the group. Each participant was then asked to explain his or her top-and bottom-ranked choices to the group. The rounds of voting continued in the same manner until consensus was reached ($80% of the votes) or until it was clear that consensus would not be reached. Between each round, after the participants were shown the results, the administrators were allowed to remove candidate definitions that decisively received a small proportion of the votes. In the final round, participants were asked to select their final top response criteria. The pediatric working group also voted on additional issues, including use of both IMACS and PRINTO core set measures and response criteria for juvenile DM that would interchange both the IMACS and PRINTO measures. Participants also voted on retesting the performance of the top candidate response criteria in future trials.
Combined pediatric and adult working group. After consensus was attained for juvenile DM response criteria, a combined working group of 22 pediatric and adult experts was formed to determine whether consensus could be reached on final, common response criteria for both juvenile DM and adult DM/PM. Common response criteria that would include both juvenile DM and adult DM/PM were considered for use in clinical trials, which might facilitate drug approvals for myositis treatment. Experienced moderators (LGR, RA, FWM, and NR) led the combined working group. For the first round of votes, the top adult and pediatric definitions from the final round of voting in each working group were considered. The online voting system was utilized again, and each participant discussed his or her top-choice candidate definition, using nominal group technique in a round-robin manner. At each round, participants were asked to select only 1 candidate top response criteria set; discussion was stopped once consensus of $80% was reached. For determining the thresholds of improvement for the selected definition, the required consensus was $70%, which was done by post-conference voting.
Results
The performance characteristics of 101 of 312 candidate definitions were excellent (sensitivity and specificity of $80%, AUC $0.90 for minimal improvement), and 30 candidate definitions also performed well in 2 clinical trials, in which they differentiated between treatment arms (P , 0.05 for minimal improvement) and differentiated the treating physician's improvement score at week 24 (P , 0.001) (15) .
Top candidate definitions for response criteria. Fourteen top-performing candidate definitions were brought to the pediatric working group for consideration at the consensus conference (Table 2 and Supplementary Tables 1 and  2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40060/abstract). These candidate criteria included 9 categorical definitions in which different criteria were set for minimal, moderate, and major improvement and 5 continuous definitions in which improvement points are given on a continuous scale that corresponds to the magnitude of improvement, with different thresholds for minimal, moderate, and major improvement. Among the 9 categorical definitions, 2 were previously published IMACS and PRINTO response criteria (9-11), 4 were newly drafted definitions based on a survey of experts, and 3 were weighted definitions. Among the continuous definitions, 2 were developed by logistic regression, and 3 were developed from the conjoint analysis survey. Among the 14 candidate criteria considered, 11 were based on relative percent change, and 3 were based on absolute percent change in the core set measures.
The performance characteristics of these 14 candidate definitions are shown in Table 2 and Supplementary  Table 1 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40060/ abstract). In the patient profiles, with expert consensus as a gold standard, all definitions presented at the conference had sensitivity and specificity of $87% (AUC $0.90) for minimal improvement (Table 2 and Supplementary Table  1) . For moderate improvement, specificity decreased but was $80% (AUC $0.88), and for major improvement specificity was generally $75% (AUC $0.84). For continuous definitions, the AUCs (from ROC curves) for the total improvement score were generally better than the AUCs (average of sensitivity and specificity) for the thresholds of minimal, moderate, and major improvement. Performance was similar between the IMACS and PRINTO core set measures for each definition.
Almost all candidate criteria were validated using the PRINTO trial at 6 months, when they could differentiate between treatment arms, with P , 0.05 for minimal improvement (Table 2 and Supplementary Table  1 ). All candidate criteria were also validated in 48 juvenile DM patients in the RIM trial (25) . All definitions could differentiate the median treating physician's improvement score at week 24 (P # 0.006).
Consensus conference voting. Among the 14 candidate definitions, 13 and 11 candidate definitions of response were promoted in the first and second voting rounds, respectively. In round 3, 6 candidate definitions were chosen, each receiving a similar number of votes. These 6 included the 3 conjoint analysis-based continuous definitions, a conjoint analysis-based weighted definition, a logistic regression absolute percent change definition, and the previously published PRINTO preliminary response criteria (8, 9) . In the fourth round of voting and discussion, participants reached consensus Table 2 . control; NA 5 not applicable. † Calculated as the area under the curve (AUC) from the receiver operating characteristic (ROC) curve for the total improvement score and the threshold for minimal, moderate, and major improvement. ‡ Calculated as the AUC from the ROC curve, using the total improvement score and the threshold cutoffs for minimal, moderate, and major improvement, which applies only to continuous definitions. § PRINTO juvenile dermatomyositis (DM) trial of prednisone alone versus prednisone with methotrexate or cyclosporine (n 5 139) (13) . ¶ Rituximab in Myositis (RIM) trial juvenile DM arm (n 5 48). Comparison of the treating physician's rating of improvement if the improvement criteria are met versus not met at week 24 (25) . A 1-point difference in physician's rating of improvement from no improvement to minimal improvement was considered not only statistically significant but also clinically significant.
# Median score for physician's rating of improvement. ** The conjoint analysis-based continuous candidate response criteria using absolute percent change in core set measures (absolute percent change model) are shown in Table 3 . These criteria are also the top response criteria for adult DM/polymyositis (PM), but with different thresholds for the total improvement score for minimal, moderate, and major improvement (18) . † † The conjoint analysis-based continuous candidate definitions using relative percent change in core set measures are shown in Supplementary Table 3 (available on 
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on final top response criteria, a conjoint analysis-based continuous model using absolute percent change in the IMACS or PRINTO core set measures (Table 3) . The total improvement score is the sum of all 6 improvement scores associated with the change in each core set measure. A total improvement score of ‡30 represents minimal improvement, a score of ‡45 represents moderate improvement, and a score of ‡70 represents major improvement.
* Either all of the International Myositis Assessment and Clinical Studies Group (IMACS) or all of the Paediatric
Rheumatology International Trials Organisation (PRINTO) core set measures may be used. Note that these response criteria are also proposed for use in combined adult DM/polymyositis (DM/PM) and juvenile DM trials (18) . For comparison, the thresholds of improvement in the total improvement score for adult DM/PM are $20 for minimal improvement, $40 for moderate improvement, and $60 for major improvement. How to calculate the improvement score: The absolute percent change ([final value -baseline value]/range 3 100) is calculated for each core set measure. For muscle enzymes, the most abnormal serum muscle enzyme level at baseline (creatine kinase, aldolase, alanine transaminase, aspartate aminotransferase, lactate dehydrogenase) is used. The enzyme range was calculated based on a 90% range of enzymes from natural history data (5,38), which for creatine kinase is 15 times the upper limit of normal (ULN), for aldolase is 6 times the ULN, and for lactate dehydrogenase, aspartate aminotransferase, and alanine transaminase is 3 times the ULN. The ULN is determined according to the individual laboratories in the participating centers. The ranges for the other core set activity measures are based on the instrument scale used (13, 15, 25) . An improvement score is assigned for each core set measure based on the absolute percent change. These are totaled among the 6 IMACS or PRINTO core set measures. The thresholds for minimal, moderate, and major improvement are provided. The total improvement score itself may also be compared among treatment arms in a trial. A total improvement score between 0 and 100 corresponds to the degree of improvement, with higher scores corresponding to a greater degree of improvement. CMAS 5 Childhood Myositis Assessment Scale; CHQ-PhS5Physical Summary Score of the Child Health Questionnaire-Parent Form 50.
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performance characteristics in the patient profiles and the trial validation for each of the top candidate response criteria presented at the conference. For the top conjoint analysis-based continuous response criteria using absolute percent change in each of the core set measures, the sensitivity and specificity in the patient profiles was generally .90% and the AUC .0.90 for both the IMACS and PRINTO measures. For the PRINTO trial, a difference in the treatment arms was detected for minimal and moderate improvement using the top response criteria, and in the RIM trial a difference in the physician's rating of improvement when the response criteria rated the patient as improved versus not improved was detected for minimal, moderate, and major improvement. Pediatric experts favored the conjoint analysisbased continuous response criteria because of the continuous improvement score that corresponds to the magnitude of improvement and provides the ability to categorize a patient's degree of change into minimal, moderate, and major improvement. The continuous model definitions also differentially weight the various core set measures, which experts thought were consistent with their assessment of the relative importance of each of the core set measures. The top response criteria were based on absolute percent change in core set measures, which was also favored by the participants because, given the various visual analog scale (VAS) measurements used in the core set measures, the absolute percent changes were more congruent than relative percent changes with actual changes that the myositis experts see in clinical practice.
Final response criteria chosen by the combined pediatric and adult working group. For this round of votes, the top 2 pediatric (Table 2 ) and adult definitions (18) were considered. Two rounds of voting resulted in final consensus response criteria, with 91% of participants voting for the conjoint analysis-based continuous response criteria based on absolute percent change in the core set measures (Table 3 ). It was agreed that the top response criteria would be used in future clinical trials that combined juvenile DM and adult DM/PM. Because the final response criteria were similar, participants favored using response criteria that would be common to juvenile DM and adult DM/PM, and they favored combined studies when possible as well as the possibility of comparing outcomes in separate studies using the same final response criteria.
Other votes. In a post-conference final vote using the Delphi method, 74% of the participants agreed to use the following pediatric threshold values for minimal, moderate, and major response in juvenile DM: total improvement score $30 (on a scale of 0-100) for minimal, $45 for moderate, and $70 for major improvement. In contrast, the final thresholds for minimal, moderate, and major response in adult DM/PM were $20, $40, and $60, respectively. The pediatric working group also reached consensus that, given the overall similarity between the IMACS and PRINTO response criteria, joint IMACS/PRINTO response criteria for juvenile DM are being proposed. The current development of the response criteria in parallel between the IMACS and PRINTO core set measures necessitates that either all of the IMACS or all of the PRINTO core set measures be used. The pediatric experts, however, committed to measure both IMACS and PRINTO core set measures in future therapeutic trials, with 92% agreement, and to continue to test the interchangeability of the IMACS and PRINTO core set measures. The group also unanimously agreed to retest the validity of the top 5 candidate definitions for response criteria and to utilize the other 4 definitions as secondary end points in future clinical trials. The top 3 of these criteria, the conjoint analysis definitions, are the same for both juvenile DM and adult DM/PM, with different thresholds of improvement (Table 3 and Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40060/abstract).
Discussion
Conjoint analysis-based continuous response criteria, based on absolute percent change in the core set measures, were developed as the consensus-and datadriven response criteria for minimal, moderate, and major improvement in juvenile DM. For the response criteria, either IMACS or PRINTO core set measures could be used. In addition, it was agreed that the same response criteria, using the IMACS core set measures but with different thresholds for improvement, would be the consensus response criteria for adult DM/PM trials and combined juvenile DM and adult DM/PM trials in the future (18) .
The comprehensive process used to develop final response criteria for minimal, moderate, and major improvement in juvenile DM included the use of large, prospective, natural history data sets for juvenile DM and data from 2 randomized controlled trials for validation, which included a wide range of disease activity and different stages of disease, from recently diagnosed to treatment-refractory patients (13, 15, 25) . The involvement of many clinical experts who had experience using the core set measures in juvenile DM patients was also critical. They provided input at several points throughout the process, including determining thresholds for improvement in core set measures by which definitions of response were drafted, achieving gold standard ratings of improvement by evaluating and developing consensus patient profiles, completing the conjoint analysis surveys to develop differential weights for the core set measures, and participating in the final consensus conference to achieve consensus for common response criteria with the greatest clinical face validity. The current response criteria (Table 3 ) also resolve the differences between PRINTO and IMACS core set measures by testing candidate definitions of response criteria in parallel using both sets of measures and showing that they are largely interchangeable, and that their performance is comparable. Moreover, this project brought both IMACS and PRINTO consortia to work together for this rare disease.
The combined group of pediatric and adult experts selected the same top-choice definition but with differing thresholds for improvement, which had very similar performance characteristics and were thought to be more appropriate for use in clinical trials that would, in the future, combine adult and pediatric patients.
The final response criteria selected, conjoint analysis-based continuous response criteria using absolute percent change in core set measures, have many advantages. For each measure, improvement points are calculated based on the level of change in that measure, and each core set measure is differentially weighted, such that changes in muscle strength and physician global activity are weighted more heavily than changes in the most abnormal enzyme value or quality of life. A total improvement score can be obtained as a continuous measure, and the means or medians of total improvement scores can be compared between treatment arms (33) . A total improvement score between 0 and 100 also corresponds to the degree of improvement, with higher scores corresponding to a greater magnitude of improvement. This score may be more sensitive to change, resulting in smaller trial sample sizes (33, 34) . Alternatively, thresholds for minimal, moderate, and major improvement have been established that allow dichotomous use of the response criteria as well. Therefore, this is truly a hybrid model that can be used as either a continuous or categorical outcome measure within the same response criteria depending on the trial design and needs of the study.
The response criteria allow input from all the core set measures instead of relying on only a few measures to determine whether a patient has experienced improvement. However, although these response criteria were developed using all 6 core set measures, the response criteria could still be used if fewer core set measures were obtained, allowing for greater flexibility in the types of patients and improvements that can occur, but we caution that the response criteria are most accurate when all 6 core set measures are used. As such, the response criteria signify a major advance in assessing improvement in therapeutic trials and other clinical research studies by providing data-driven response criteria that were developed by consensus of major stakeholders in the field who come from all over the world.
Prior response criteria in rheumatic diseases have included relative percent change (35, 36) , whereas myositis response criteria are based on absolute percent change. The experts favored the use of absolute percent change for various reasons. In this study, several core set measures used a 10-cm VAS, and the experts thought that absolute percent change better represents the degree of change they see in clinical practice. Moreover, absolute percent changes can be calculated when the baseline core set measure is 0 and give similar results for similar degrees of change at either end of the VAS.
The participants also favored using the same response criteria for juvenile DM and adult DM/PM, but with cut points or thresholds for improvement specific to pediatric or adult patients. Having common response criteria facilitates the potential to conduct combined clinical trials, such as the RIM trial (25) , and to compare the outcomes of trials and studies conducted separately. Participants agreed to include other top-performing definitions that were highly rated as secondary end points for future clinical trials. Among these were not only other conjoint analysis-based continuous models but also the published PRINTO preliminary response criteria (10, 11) . Future work should also evaluate whether a baseline composite score threshold derived from the PRINTO or IMACS core set measures could be used as inclusion criteria for future clinical trials.
Limitations of the present work include the lack of a placebo group in the RIM trial. For this reason, the physician's assessment of improvement at 6 months was used instead. We were fortunate to have another controlled clinical trial for juvenile DM that had 3 treatment arms to use for external validation (13) , in which we evaluated the ability of the candidate definitions to differentiate between treatment arms. Although thresholds for major improvement were developed and validated in fewer patients, we believe that it was sufficient given that 29% of patients had major improvement in patient profiles, and 17% had major improvement in the clinical trials used for validation. The final conjoint analysis-based continuous response criteria also do not address worsening in the core set measures; however, this generally does not affect the outcome, because when patients are rated as improved, no more than 1 or 2 measures worsen in our clinical data sets. Also, although we tested the interchange of IMACS and PRINTO core set measures, we tested these variations as 920 RIDER ET AL 2 parallel core set measures but did not examine intermixing the PRINTO and IMACS core set measures. Further work to examine the interchangeability of the IMACS and PRINTO core set measures will be needed. The data sets used to develop the new response criteria primarily contained information about patients with a recent diagnosis or those experiencing a disease flare, and further work is needed to determine how the response criteria perform in patients with longstanding disease or those with significant disease-related damage. Finally, although application of the criteria might seem cumbersome, as regularly done for JIA and RA, the evaluation of improvement will be facilitated by appropriate dedicated software or "apps," or in the future, by simplification of the manner in which the core set measures are evaluated (e.g., similar to the Juvenile Arthritis Disease Activity Score for JIA) (37) . The time required to apply these criteria is estimated to be 25-35 minutes to complete the core set measures at each visit (1) and 2-3 minutes to hand-calculate the total improvement score and degree of response. Both IMACS and PRINTO are developing a web-based tool as well as a downloadable calculator that will allow easy administration of the response criteria and immediate calculation. The apparent complexity is, however, counterbalanced by the establishment of different validated levels of improvement, which constitute the real novelty of this project and which have never been validated as such for either RA or JIA, despite being regularly reported in clinical trials.
In summary, conjoint analysis-based continuous response criteria that establish different thresholds for minimal, moderate, and major improvement and utilize the absolute percent change in core set measures were chosen as the consensus response criteria for juvenile DM and were validated using both natural history and trial data. These response criteria should be highly acceptable and widely used given that they were developed with consensus among many myositis experts worldwide. They should be sensitive in detecting differences in improvement and in quantitating the degree of improvement, as seen in the 2 clinical trials. Thus, clinical trials that test new therapies for juvenile DM should be easier to design, conduct, and compare.
